Withdrawn from XPRIZE Healthspan participation. Although the semi-final trial results were highly favorable, it is deemed that participation does not lead to maximizing future business value, considering the impact of contract terms and the advantage of the new drug RS5614. The impact on the 2027 fiscal year results is under review.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4889","jir_company_name":"Renascience Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-08-11","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4889-20260811-01.pdf","jir_short_summary":"Withdrawn from XPRIZE Healthspan participation. Although the semi-final trial results were highly favorable, it is deemed that participation does not lead to maximizing future business value, considering the impact of contract terms and the advantage of the new drug RS5614. The impact on the 2027 fiscal year results is under review.","jir_summary":"### Key points of the news\nRenascience Inc. announced its withdrawal from XPRIZE Healthspan, which aims to extend healthy lifespan. Although the semi-final trial results were very favorable, it did not secure a prize, and concerns about contractual terms such as alignment with existing therapies, data ownership, and licensing grants led to withdrawal. Even considering the advantage of RS5614, participation is not deemed to directly maximize business value.\n\n### Outlook and impact\nDespite withdrawing from XPRIZE Healthspan, the company will continue its anti-aging and longevity research and business activities. Based on the semi-final results, plans are in place for a large-scale clinical trial to advance drug development for aging-related diseases. The impact on the 2027 fiscal year results is being examined, and any additional information will be disclosed promptly.","jir_financial_highlights":"Unknown: Unknown (Unknown)","jir_category":"","jir_hashtags":"#Renascience, #TreasuryStock, #ExecutiveAppointments, #LongTermR&D","jir_key_figures":"RS5614: Unknown (specific figures are unknown)\nXPRIZE Healthspan: withdrawal decision (announced on 2026-08-11)\nImpact on 2027 fiscal year: under review","jir_meta_title":"Renascience: Notice of Withdrawal from XPRIZE Healthspan | August 2026","jir_meta_description":"Renascience announces withdrawal from XPRIZE Healthspan. Semi-final results were highly regarded, but it did not qualify for the prize; the impact on future business strategy and the 2027 fiscal year is under review. Details are in the main text.","jir_og_title":"Renascience: Notice of Withdrawal from XPRIZE Healthspan","jir_og_description":"Renascience withdraws from XPRIZE Healthspan. Despite highly rated semi-final results, decision aligns with maximizing business value. Upcoming clinical trial plans and impact disclosed.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":57877,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-101705","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n